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Summary
Robot-assisted radical prostatectomy causes discomfort in the immediate postoperative period. This randomised
controlled trial investigated if intrathecal bupivacaine/morphine, in addition to general anaesthesia, could be
beneﬁcial for the postoperative quality of recovery. One hundred and ﬁfty-ﬁve patients were randomly allocated
to an intervention group that received intrathecal 12.5 mgbupivacaine/300 lgmorphine (20%dose reduction in
patients > 75 years) or a control group receiving a subcutaneous sham injection and an intravenous loadingdose
of 0.1 mg.kg1 morphine. Both groups received standardised general anaesthesia and the same postoperative
analgesic regimen. The primary outcome was a decrease in the Quality of Recovery-15 (QoR-15) questionnaire
score on postoperative day 1. The intervention group (n = 76) had less reduction inQoR-15 on postoperative day
1; median (IQR [range]) 10% (1–8 [60% to 50%]) vs. 13% (5–24 [6% to 50%]), p = 0.019, and used less
morphine during the admission; 2 mg (1–7 [0–41 mg]) vs. 15 mg (12–20 [8–61 mg]), p < 0.001. Furthermore,
they perceived lower pain scores during exertion; numeric rating scale (NRS) 3 (1–6 [0–9]) vs. 5 (3–7 [0–9]),
p = 0.001; less bladder spasms (NRS 1 (0–2 [0–10]) vs. 2 (0–5 [0–10]), p = 0.001 and less sedation; NRS 2 (0–3 [0–
10]) vs. 3 (2–6 [0–10]), p = 0.005. Moreover, the intervention group used less rescue medication. Pruritus was
more severe in the intervention group;NRS 4 (1–7 [0–10]) vs. 0 (0–1 [0–10]), p = 0.000.Weconclude that despite a
modest increase in the incidence of pruritus, multimodal pain management with intrathecal bupivacaine/
morphine remains a viable option for robot-assisted radical prostatectomy.
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Introduction
Robot-assisted radical prostatectomy causes considerable
discomfort, mainly during the ﬁrst postoperative day. The
discomfort originates from abdominal pain, bladder spasm
and transurethral catheter irritation [1]. Various techniques
such as dorsal penile nerve block, transversus abdominus
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plane block, administration of intravesical ropivacaine,
suprapubic catheters and intrathecal morphine were
investigated and resulted in moderate analgesic effects [2–
6]. This emphasises the necessity for improvement of
postoperative care in the ﬁrst days after robot-assisted
radical prostatectomy.
An ideal analgesic method has maximal beneﬁt and
few side-effects, and this is likely to be reﬂected in the
quality of recovery. The analgesic effects of intrathecal
morphine have been demonstrated to last for 20–48 h [6, 7].
The side-effects, however, have not been studied
sufﬁciently in this type of surgery. One of the side-effects of
intrathecal morphine is urinary retention. This is relieved as
a direct result of this procedure, since all patients receive a
urinary catheter following surgery [8]. Moreover, bladder
spasm-related discomfort may be effectively reduced by
intrathecal morphine, since it reduces bladder contractions
[9]. These properties of intrathecal morphine suggest that it
is a potentially suitable technique for improving the quality
of recovery after robot-assisted radical prostatectomy.
The aimof this studywas therefore to evaluate quality of
recovery after administration of intrathecal bupivacaine/
morphine following robot-assisted radical prostatectomy
surgery. Besides length of stay and surgical conditions, this
study investigated the positive and negative effects of
intrathecal morphine. We hypothesised that, due to a
reduction in pain and discomfort, intrathecal bupivacaine/
morphine would lead to improved quality of recovery on the
ﬁrst postoperative day comparedwith the control group.
Methods
This study was a single-centre, observer- and patient-
blinded randomised clinical trial performed in a teaching
hospital and national referral centre for robot-assisted
radical prostatectomy (Maasstad Hospital, Rotterdam, the
Netherlands). The study was approved by the local ethics
committee (Toetsingcommissie Wetenschappelijk
Onderzoek Rotterdam e.o., the Netherlands) and the
CCMO (Dutch abbreviation for Central Committee on
Research involvingHuman Subjects).
All patients scheduled for robot-assisted radical
prostatectomy with or without pelvic lymph node dissection
between October 2016 and June 2018 were eligible for
participation. Exclusion criteria were: age < 18 y; contra-
indications to study medication (such as allergy or
glomerular ﬁltration rate < 30 ml.min1); contra-indications
to spinal anaesthesia (such as severe aortic stenosis,
coagulation disorders, increased intracranial pressure);
scheduled postoperative ICU admission; and patient refusal
to participate.
Patients were informed about the study during the pre-
operative screening. Weeks before surgery the patients
were called for further explanation, informed consent and
the baselineQuality of Recovery-15 (QoR-15) questionnaire.
Patients provided written informed consent before the start
of randomisation in the pre-operative holding area.
Randomisation was by the use of sealed, opaque
envelopes. An independent colleague randomised these
envelopes in blocks of 10with a 1:1 ratio to produce an equal
distribution of intervention across the whole study period.
The envelopes were stacked and stored. When an included
patient arrived in the holding area, the upper envelope was
opened by the attending anaesthetist. The patient, surgical
team, nurses on the ward and researchers were all blinded.
Only the attending anaesthetic team and the nurse in the
post-anaesthesia care unit (PACU) were aware of group
allocation. They were not involved in further patient care or
data collection, other than ﬁlling in the case record form
during the surgical procedure and recovery phase.
All patients received 1000 mg intravenous (i.v.)
cefazolin 30 min before surgery. No sedative
premedication was given. In the operating theatre the
patients received standard monitoring. After the time-out,
the surgical team left the theatre for blinding purposes. In
accordance with random allocation, the patient received
either an intrathecal injection of bupivacaine/morphine or a
shamprocedure.
In both treatment allocation groups, the patient was
placed in an upright sitting position, the skin over the lumbar
region of the backwas cleanedwith chlorhexidine and sterile
drapes were positioned. In both groups, the skin was
inﬁltratedwith 3 ml lidocaine 1%. In the intervention group, a
sterile 27-G pencil-point needle (Pencan; Braun Melsungen
AG, Melsungen, Germany) was inserted at the L2–3 or L3–4
interspace. After obtaining cerebrospinal ﬂuid, medication
was administered with a single injection; 12.5 mg isobaric
bupivacaine and 300 lgmorphine in 5 ml. For patients over
75 years of age, 10 mg isobaric bupivacaine and 240 lg
morphine in 4 ml were given. The medication was prepared
by the Pharmacy Department. No additional i.v. morphine
was administeredduring the procedure.
Patients in the control group received a sham
procedure after the aforementioned skin inﬁltration with
3 ml lidocaine 1%. After this, the anaesthetist pressed on
the skin with a ﬁnger to simulate intrathecal injection. The
patients who were randomly allocated to the control group
received 0.1 mg.kg1 morphine i.v. during surgery, which
was standard practice in our hospital.
For both groups, standardised general anaesthesia was
administered immediately after the spinal puncture. After
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pre-oxygenation, 0.4 lg.kg1 sufentanil, 2 mg.kg1
propofol and 0.6 mg.kg1 of rocuronium were
administered and the trachea intubated. Thereafter, the
patient was positioned in lithotomy, the operative ﬁeld
disinfected and sterile drapes positioned. A transurethral
catheter was inserted. Pneumoperitoneumwas achieved by
insufﬂation of CO2 up to a pressure of 15 mmHg through a
12-mm camera trocar inserted through a periumbilical
incision. After insertion of the remaining ﬁve trocars (three
8 mm robotic trocars, a 15-mm and a 5-mm assisting
trocar), intra-abdominal pressure was decreased to
12 mmHg and the patient placed in the Trendelenburg
position. In this position, the robot surgery system (Da Vinci
Si System, Intuitive Surgical, Sunnyvale, CA, USA) was
docked and surgery commenced.
Ten micrograms of i.v. sufentanil was administered
when an increase in heart rate or blood pressure > 10%
occurred in comparison with a stable phase during surgery.
Rocuronium 10 mg i.v. was administered when ventilator
desynchronisation or abdominal wall contraction occurred.
Vaso-active medication was given at the discretion of the
attending anaesthetist (i.e. phenylephrine, ephedrine or
noradrenaline). Every patient received an i.v. infusion of
500 ml lactated Ringer’s solution with a targeted ﬂuid
balance of less than 750 ml surplus.
Standard medication of 1000 mg paracetamol,
1000 mg metamizol, 0.625 mg dehydrobenzperidol and
4 mg ondansetron was given i.v. before the end of surgery.
A train-of-four measurement was performed in order to
exclude residual neuromuscular blockade after surgery. If
necessary, rocuronium was antagonised with atropine/
neostigmine or sugammadex at the discretion of the
anaesthetist. After completion of surgery, the patient’s
trachea was extubated in the operating room and
transferred to PACU for at least 30 min of observation.
In PACU, a nurse (unblinded to the randomisation)
administered 2.5 mg morphine i.v. if the pain score was > 4
on a numeric rating scale (NRS). This was evaluated every
10 min and morphine administration was repeated if
necessary up to a maximum of 20 mg. If the patient was still
in pain after 20 mg of morphine, other analgesics were
administered at the discretion of the attending anaesthetist
and consisted of i.v. esketamine, i.v. clonidine, oral
oxybutynin or i.v. hyoscine. Pain scores were registered on
arrival and discharge from PACU. Nursing staff were able to
administer an additional dose of 0.625 mg i.v.
dehydrobenzperidol for nausea according to their own
clinical judgement. Similarly, 30 mg of i.v. propofol was
allowed for pruritus. In both treatment arms the patient-
controlled intravenous analgesia (PCA) pump was
connected and instructions given to the patient when they
were sufﬁciently awake and pain free. It was set to
administer 1 mg of morphine i.v. per bolus with a lockout
time of 6 min. Discharge to the ward was allowed when the
patient had an Aldrete score > 8 and pain, nausea and other
side-effects werewellmanaged.
All patients received 2 l.min1 of oxygen by nasal
cannulae during the ﬁrst night. Oxygen was to be increased
when SaO2 < 92%. To reduce the risk of late respiratory
depression, patients in both groups were not allowed to
receive benzodiazepines or opioids other than PCA
morphine. No other precautions were taken to prevent late
respiratory depression. Postoperative pain treatment
included paracetamol up to 4000 mg.day1 and metamizol
1000 mg. Morphine administered by the PCA system was
prescribed for postoperative analgesic management. The
PCA system was stopped on the ﬁrst postoperative day
(POD 1). Ondansetron 4 mg was administered when
required for nausea and pruritus, 5 mg of oxybutynin was
prescribed for bladder spasms. The urinary catheter
remained in situ for 7 days after surgery.
Patients were discharged home after aminimum of one
night in hospital when they: were able to mobilise; achieve
adequate pain control with oral medication; able to eat and
drink; had vital signs within normal limits; and had sufﬁcient
home care.
The primary outcome was percentage decrease in
QoR-15 at POD 1 from the baseline score that was
established within the weeks before surgery. On POD 1, the
QoR-15-questionnaire was assessed by a blinded
anaesthetic nurse. Furthermore, the QoR-15 on POD 1 was
analysed both as an absolute decrease and as a single
score. The ﬁve subdomains of QoR-15 measurements were
also analysed [10].
The QoR-15 (range 0–150, in which 150 is the best
possible outcome) is a validated questionnaire commonly
used in the peri-operative setting and recommended as an
outcomemeasure by the ESA-ESICM joint taskforce on peri-
operative outcome measures [11]. The QoR-15 is reported
as absolute decrease, relative decrease and single score
[10]. We chose the relative decrease in percentage as the
primary outcome measure because population values of
absolute thresholds for QoR-15 in patients undergoing
robot-assisted radical prostatectomy were not available
when the study was initiated. After initiation of the study, a
minimal clinically important difference was deﬁned as 8.0
and an acceptable symptom state of 118 was determined
[12].
The intra-operative secondary outcomes (duration of
different stages of the anaesthesia, sufentanil and
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rocuronium administration, i.v. ﬂuid administration, blood
loss, pain scores and complications) were noted on a case
record form that was ﬁlled in by the anaesthetic team and
PACU nurse (who were unblinded) during surgery and the
recovery phase. Furthermore, the attending urologist
(blinded) was asked to score the surgical difﬁculty of the
procedure on a numeric rating scale (NRS), ranging from 0
(easy) to 10 (very difﬁcult) after surgery. The PCA systemwas
checked electronically for total morphine consumption and
bolus demands.
For the postoperative secondary outcomes, an
anaesthetic nurse (blinded) visited the patients on POD 1. In
addition to the QoR-15, seven items related to the potential
beneﬁts and side-effects of intrathecal morphine: physical
discomfort; pain during exertion; bladder spasms;
sedation; sleep; pruritus; and general satisfaction – were
recorded with a NRS ranging from 0 (low or absent) to 10
(high or severe) (see also Supporting Information, Data S1).
One week after surgery, a trained medical
secretary (blinded), telephoned the patient to assess
the QoR-15 on postoperative day 7 (POD 7).
Additionally, 12 questions were asked regarding the
hospital admission in a retrospective manner on a NRS
ranging from 0 (low or absent) to 10 (high or severe,
see also Supporting Information, Data S1). These 12
questions consisted of the same seven items asked on
POD 1. The objective of these seven questions was to
assess recollection of symptoms after a week. The ﬁve
other items inquired about: nausea; pain at rest;
current use of analgesics; and the current state of
physical and mental abilities.
Clinical follow-up, which included occurrence of
complications, pathology results and laboratory results
(serum creatinine, haemoglobin level, C-reactive protein
and leucocyte count) were obtained from the electronic
hospital medical record. The duration of follow-up for
complications was 2 months after surgery. Respiratory
depression was deﬁned as that for which medical
intervention was necessary.
Thresholds for QoR-15 in patients undergoing
robot-assisted radical prostatectomy were not available
at the time of initiation of the study; we therefore
estimated a decrease in QoR-15 at POD 1 of 35% in
the control group and 25% in the intervention group,
with a standard deviation of 16%. We calculated that
160 patients (134 patients with 20% loss to follow-up)
were needed in total for a two-sided power of 95%
and a p value of 0.05.
Data were analysed for normal distribution and Mann–
Whitney U-tests were performed for continuous data. For
ordinal data, a Fisher’s exact test was used. A p value < 0.05
was deemed statistically signiﬁcant. A p value < 0.02 was
deemed statistically signiﬁcant for secondary outcomes
after correcting for multiple testing. An intention-to-treat
and per-protocol analysis was performed as a sensitivity
analysis to detect difference resulting from protocol
violations. Values were calculated with SPSS version 21.0
(IBM, Armonk, NY, USA) and graphics were produced using
GraphPad Prism version 7.1 (GraphPad Software, San
Diego, CA, USA).
Results
Four hundred and ﬁfty-nine patients were screened, of
whom 12were not included and 287 declined to participate
(Fig. 1). Three patients in the intervention group withdrew
consent after random allocation. All attempts at intrathecal
injection in the intervention group produced return of
cerebrospinal ﬂuid through the needle. Five patients in the
intervention group accidently also received an i.v. loading
dose of 0.1 mg.kg1 morphine. Five patients received a
robot-assisted simple prostatectomy (two in the
intervention group, three in the control group). These
patients were included in the intention-to-treat analysis, and
a per-protocol analysis showed no difference in morphine
consumption and QoR-15 scores for these violations. No
other protocol violations were observed. Baseline
characteristics are displayed in Table 1. The groups were
comparable; only lymph node dissection was performed
more often in the intervention group.
The completion rate for QoR-15 was 89.7% pre-
operatively, 93.5% for POD 1 and 99.4% for POD 7. Since
both the pre-operative and the POD 1 QoR-15 were
required to assess primary outcome, 89.6% in the
intervention group and 77.2% in the control group were
available for analysis of the primary outcome (Fig. 1).
The percentage decrease in QoR-15 on POD 1 was
signiﬁcantly less in the intervention group than the
control group; 10% (1–8 [60% to 50%]) vs. 13% (5–24
[6% to 50%]), p = 0.019. Absolute values of QoR-15
were similar; 123 points (106–137 [72–150]) vs. 118
points (105–130 [66–150]), p = 0.077 at POD 1 (Fig. 2).
The absolute decrease in QoR-15 and subdomains are
presented in Table 2. Analyses of QoR-15 subdomains
showed that only the decline in ‘pain’ was signiﬁcantly
lower in the intervention group than in the control
group on POD 1 (Table 2). All the absolute values and
individual questions of the QoR-15 are described in the
Supporting Information Data S1.
Closer inspection of the domain ‘pain’ (range from 0 to
20, 0 = severe pain, 20 = no pain) on POD 1 showed that
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the number of patients with extreme pain (scores < 10) was
decreased; 13 (18.3%) vs. 2 (2.8%), p = 0.002 in the
intervention and control groups, respectively.
The intervention group had less pain as assessed
by the NRS and consumed less opioids than the
control group on POD 1 (Table 3). Only one patient
(allocated to the control group) received additional
dehydrobenzperidol for treatment of nausea. No
treatment for pruritus was necessary in PACU. There
were no differences regarding the surrogate markers
for laparoscopic workspace.
Table 2 shows the results of the additional questions
asked on POD 1. On the ﬁrst postoperative day, the
intervention group reported less pain during exertion, less
severe bladder spasms, less sedation, but more pruritus
than the control group. No patient required treatment for
pruritus, and only one patient (allocated to the intervention
group) received additional treatment for nausea. No
Figure 1 Flowdiagramof the participants of the study. Since the primary outcomewas a pairedmeasurement, analysis was
performed onlywhen both the pre-operativeQuality of Recovery (QoR)-15 and theQoR-15 on postoperative day 1were
available. Other outcomemeasures were analysedwhen available.
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difference in severity of nausea or general satisfaction was
detected between groups. Furthermore, no differences in
laboratory results such as creatinine levels, C-reactive
protein or haemoglobin values were detected (see also
Supporting Information, Data S1).
There was no signiﬁcant difference in QoR-15
(including subdomains) on POD7 (Fig. 2). The retrospective
scores of symptom severity regarding the hospital
admission showed lower scores than on POD 1 in both
groups. Only the difference for the severity of pruritus
remained (Table 2). There was no difference in the use of
analgesics one week after surgery (p = 0.137); patients
used no analgesics at all (33% vs. 51%), only paracetamol
(62% vs. 45%) or paracetamol with the addition of non-
steroidal anti-inﬂammatory drugs or opioids (5% vs. 4%) for
the intervention and control groups, respectively. Aminority
of patients felt physically limited in their activities beyond
the limitations set by the urologist (16% vs. 15%, p = 1.000).
Perceived mental restrictions were similar in both groups
(p = 0.347); if patients reported them, they were minor (9%
vs. 6%) ormoderate (1% vs. 5%).
Hospital length of hospital stay was similar in both
groups; median (IQR [range]) 1 (1–2 [1–3]) day vs. 1 (1–2 [1–
3]) day, p = 0.490. No patient had clinically-relevant
respiratory depression.
Sub-group analysis for prostatectomy with or without
lymph node dissection showed similar results as the total
group formorphine consumption andQoR-15 at POD1.
Discussion
This study showed that QoR-15 decreased less in patients
who received intrathecal bupivacaine/morphine than in the
control group after robot-assisted radical prostatectomy.
Furthermore, the intervention decreased opioid
consumption, pain, sedation, bladder spasms, use of rescue
analgesia and oxybutynin administration on POD 1. The
intervention especially reduced the number of patients in
severe pain. Pruritus was increased in the intervention
group compared with control. No difference in outcomes
could be detected one week after surgery. Addition of
lymph node dissection to the robot-assisted radical
prostatectomy did not affect the outcomes.
Table 1 Baseline characteristics. Values aremedian (IQR [range]) or number (proportion).
Intervention Control
n = 76 n = 79
Age; years 67 (63–70 [50–78]) 66 (61–71 [44–82])
BMI; kg.m–2 26.3 (25.0–29.7 [20.9–37.0]) 26.2 (24.6–28.1 [18.8–33.3])
ASAphysical status; (1/2/3) 22 (29%)/42 (55%)/12 (16%) 27 (34%)/43 (54%)/9 (11%)
Malignancy 73 (96%) 75 (95%)
T2 47 (64%) 53 (71%)
T3 26 (36%) 22 (29%)
Lymphnodedissection 36 (47%) 21 (27%)
Durationof surgery;min 129 (103–160 [60–263]) 133 (106–150 [71–259])
Durationof PACUadmission;min 57 (40–73 [24–341]) 60 (46–70 [25–147])
Pre-op PSA; ng.l1 9.7 (6.7–13.1 [0.5–90.0]) 8.1 (6.5–12.2 [1.3–35.4])
Days betweenbaselineQoR-15 andday of surgery 11 (5–18 [0–43]) 10 (5–20 [0–45])
BMI, bodymass index; PACU, postoperative care unit; PSA, prostate speciﬁc antigen,QoR-15:Quality of Recovery-15.
Figure 2 The total Quality of Recovery (QoR)-15 scores per
time-point. The data are presented asmeanwith SD error
bars. The percentage and absolute decrease between pre-
operativeQoR-15 andpostoperative 1were different
(p = 0.019 and p = 0.013) between the intervention and
control groups. Therewere no signiﬁcant differences
between absolute values between the groups. A score of
118 (dashed line) is deﬁned as acceptable symptom state
[12].
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The present study showed a signiﬁcant difference in
patient decreases in QoR-15 between groups, but not
absolute values of QoR-15. Changes relative to baseline
value are preferred because it addresses individual patient
changes and corrects for differences within a group [11, 13].
Still, the difference between groups is marginal, the
decrease in QoR-15 was less than estimated in the sample
size calculation and the absolute scores were comparable
with ‘minor’ or ‘intermediate surgery’ [12]. As such, these
ﬁndings indicate that the intervention had a limited effect on
theQoR-15.
A clinically important effect was found in pain
reduction. The distribution of scores in the domain ‘pain’
showed that the number of patients in pain was reduced,
which led to a six-fold decrease in patients in severe pain
(domain ‘pain’ < 10). In our opinion, this is the value
of the intrathecal bupivacaine/morphine combination.
Furthermore, morphine consumption, rescue analgesia,
rescue oxybutynin and bladder spasms were reduced in the
intervention group compared with the control group. This
shows that rescue analgesia is not as effective as intrathecal
bupivacaine/morphine in reducing pain and bladder
spasms after robot-assisted radical prostatectomy.
Bae et al. investigated the use of 300 lg intrathecal
morphine in 30 patients undergoing robot-assisted radical
prostatectomy and measured morphine consumption as
the primary outcome [6]. They found a median reduced
morphine consumption of 12 mg and reduced pain scores
in the intervention group. The current study conﬁrmed these
ﬁndings in a larger sample and added some other useful
features. Firstly, bupivacaine was added to the intrathecal
morphine, which prolongs the analgesic effect [14]. No
disadvantages of the bupivacaine were observed, such as
severe haemodynamic compromise or residual motor
blockade that prevented mobilisation. Secondly, in the
current study paracetamol and non-steroidal anti-
Table 2 Decline in Quality of Recovery (QoR-15) and scores for the additional questions. The QoR-15 outcomes are the
absolute decline compared with the pre-operative QoR-15. A negative value indicates an increase in QoR-15 score. The
additional questions are in numeric rating scales (NRS) from 0 to 10, where 10 signiﬁes maximal agreement with the
statement. For postoperative (POD) 7, it was explicitly mentioned that the additional questions regarded hospital admission.
Values are median (IQR [range]). [Correction added on 9 Jan 2020, after ﬁrst online publication: In Table 2, under QoR-15 ;
Intervention and Domain ‘pain’; Intervention and Control, error in data now revised in this version.]
POD1 POD7
Intervention Control p value Intervention Control p value
QoR-15 (absolute decrease) n = 69 n = 61 n = 72 n = 67
QoR-15 14 (2–25
[47 to 70])
18 (7–35
[9 to 64])
0.013 7 (1–17
[37 to 70])
10 (3–19
[–11 to 63])
0.197
Domain ‘pain’ 2 (0–4
[13 to 14])
6 (3–9
[4 to 14])
0.000 2 (0–3
[17 to 14])
2 (0–4
[4 to 20])
0.352
Domain ‘physical comfort’ 4 (0–11
[9 to 25])
6 (210
[6 to 23])
0.170 2 (1 to 4
[11 to 23])
2 (05
[9 to 16])
0.430
Domain ‘physical independence’ 3 (08
[2 to 20])
5 (19
[1 to 18])
0.124 3 (1.040
[2 to 15])
3 (14
[3 to 10])
0.557
Domain ‘psychological support’ 0 (4 to 0
[13 to 10])
0 (1 to 0
[10 to 16])
0.084 0 (3 to 0
[13 to 6])
0 (0 to 1
[10 to 8])
0.104
Domain ‘emotional support’ 2 (1 to 5
[6 to 17])
2 (2 to 7
[10 to 26])
0.624 0 (1 to 5
[8 to 26])
1 (04
[12 to 19])
0.708
Additional questions (NRS) n = 66 n = 71 n = 76 n = 78
Severity of physical discomfort 5 (2–7 [0–9]) 6 (3–7 [0–10]) 0.079 3 (1–6 [0–10]) 4 (2–6 [0–10]) 0.235
Severity of pain during exertion 3 (1–6 [0–9]) 5 (3–7 [0–9]) 0.001 3 (2–7 [0–10]) 5 (2–7 [0–10]) 0.072
Severity of bladder spasms 1 (0–2 [0–10]) 2 (0–5 [0–10]) 0.001 0 (0–4 [0–10]) 0 (0–6 [0–10]) 0.098
Severity of sedation 2 (0–3 [0–10]) 3 (2–6 [0–10]) 0.005 1 (0–3 [0–10]) 2 (0–5 [0–8]) 0.339
Severity of insomnia 1 (0–6 [0–10]) 5 (1–7 [0–10]) 0.070 1 (0–6 [0–10]) 5 (1–7 [0–10]) 0.174
Severity of pruritus 4 (1–7 [0–10]) 0 (0–1 [0–10]) < 0.001 1 (0–5 [0–9]) 0 (0–0 [0–9]) < 0.001
General satisfaction 9 (8–10 [0–10]) 8 (7–10 [0–10]) 0.820 8 (8–10 [1–10]) 9 (8–10 [0–10]) 0.414
Severity of nausea n/a 0 (0–3 [0–10]) 0 (0–3 [0–10]) 0.365
Severity of pain in rest n/a 0 (0–3 [0–9]) 0 (0–3 [0–9]) 0.085
n/a, not available.
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inﬂammatory drugs were administered as part of a
multimodal postoperative analgesic regimen. This may
have reduced the opioid-sparing effect attributed to
intrathecal morphine, because a multimodal analgesic
regimen also leads to less opioid consumption. Still, the
opioid-sparing effects of the intrathecal morphine persisted
longer than the effects of the paracetamol and non-steroidal
anti-inﬂammatory drugs. Finally, due to the ﬁve-fold
increase in the number of participants compared with the
earlier study, the present study allowed detection of
differences in side-effects and sub-group analysis for
patients with lymph node dissection.
The increased severity of pruritus in the intervention
group is clinically relevant and in accordance with other
studies [15]. This appeared not to affect the QoR-15,
probably because pruritus is not included in QoR-15.
Ondansetron and dehydrobenzperidol were administered
as prophylactic drugs against pruritus [16]. Remarkably, no
patient requested treatment for these side-effects. The
continuation of 5-HT3 antagonists at ﬁxed times could have
further decreased the incidence and severity of pruritus, but
this aspect of management was not included in the study
protocol [17]. Additionally, management of patients’
expectations by providing information and explanationmay
have limited this discomfort, since unexpected symptoms
may be perceived as more severe [18]. Postoperative
nausea was not increased by the use of intrathecal
morphine, even though this is a well-known side-effect [19].
This could be explained to some extent by the prophylactic
use of ondansetron, dehydrobenzperidol and the male sex
of the study population [16].
Our hypothesis that intrathecal bupivacaine would lead
to increased laparoscopic workspace due to motor block is
not supported by this study. Even though wewere unable to
measure true laparoscopic workspace in this study, the
surrogate markers did not differ. Nevertheless, the addition
of bupivacaine might have the beneﬁcial effects of
producing analgesia before the onset of the intrathecal
morphine and prolonging duration of action [14], but this
was not investigated in the present study.
The most feared side-effect of intrathecal morphine,
late respiratory depression, did not occur in any patients.
Incidence is difﬁcult to estimate, since the deﬁnition of
respiratory depression varies from a SaO2 < 94% and/or
PaCO2 > 6 kPa to a respiratory rate < 6 breaths permin [20].
Most reported cases of late respiratory depression with the
use of < 500 lg intrathecal morphine required no
intervention [19]. Therefore, we did not employ any speciﬁc
monitoring for this complication, since clinically-relevant
respiratory depression is unlikely to occur more often with
low-dose intrathecal morphine (< 500 lg) than with PCA
morphine [19, 21]. Sedatives and opioids (other than as
needed in PCA) were contra-indicated on the night after
surgery due to the potential to interact with intrathecal
morphine and cause severe respiratory depression [22].
This study has several limitations. One limitation is the
protocol violation in ﬁve patients who received an i.v.
loading dose of morphine in addition to the intrathecal
Table 3 Secondary outcomes. Values aremedian (IQR) [range] or number (proportion).
Intervention Control
p valuen = 76 n = 79
Opioid consumption
Intra-operative sufentanil use; lg 35 (25–45 [15–100]) 45 (35–50 [20–90]) < 0.001
Intra-operativemorphine consumption;mg 0 (0–0 [0–10]) 9 (8–10 [5–20]) < 0.001
Morphine consumption in PACU;mg 0 (0–0 [0–16]) 0 (0–0 [0–14]) 0.053
Morphine consumption per PCAduring hospital stay;mg 2 (1–6 [0–41]) 5 (2–11 [0–51]) < 0.001
Totalmorphine consumption during hospital stay;mg 2 (1–7 [0–41]) 15 (12–20 [8–61]) < 0.001
Pain/non-opioid analgesics
Pain scores on recovery area; NRS 0 (0–0 [0–5]) 0 (0–4 [0–8]) < 0.001
Additional non-opioid analgesia 4 (5.3%) 22 (27.8%) < 0.001
Additional oxybutynin on theward 23 (30.3%) 40 (50.6%) 0.014
Laparoscopicworkspace
Rocuronium consumption;mg 50 (50–58 [25–105]) 50 (50–60 [35–115]) 0.278
Difﬁculty of surgery;NRS 3 (1–4 [0–10]) 4 (2–6 [0–9]) 0.119
Duration of surgery;min 129 (105–160 [60–263]) 133 (105–150 [71–259]) 0.987
Estimatedblood loss;ml 200 (140–325) [5–1300] 200 (150–400 [0–2300]) 0.623
PACU, post-anaesthesia care unit; PCA, patient-controlled analgesia; NRS, numeric rating scale.
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bupivacaine/morphine. These patients were monitored for
12 h in PACU for late respiratory depression, but this did not
occur. Since this might have affected the quality of recovery,
a sensitivity analysis was performed that showed the same
results. A second limitation is the omission of 5-HT3
antagonist prophylaxis against pruritus on the ward, which
could reduce incidence and severity of pruritus, and
perhaps further increase the quality of recovery. A third
limitation is that the anaesthetic team and PACU nurses
were unblinded for group allocation, which could have
inﬂuenced the administration of additional analgesics or the
scoring of pain. However, this was deemed inevitable to
guarantee patient safety in case of emergencies. A fourth
limitation was the loss of QoR-15 data. This was caused by
the incorporation of the study into daily practice, during
which forms were lost or patients had no time to answer the
questionnaire by phone and were not reached a second
time before surgery. Finally, the proportional decrease in
QoR-15 was chosen as the primary outcome. Other values,
such as the minimally clinically important difference and
acceptable symptom state were determined during the
execution of this study and were therefore not used in the
power analysis.
The current trial offers two recommendations for
subsequent studies. First, the QoR-15 appears to be a
difﬁcult instrument to interpret. Its main advantage is the
overall view of patients’ experience, measured by ﬁve
subscales. The disadvantage is the possibility that if an
intervention reduces one item it may be obscured by the
other items, reducing sensitivity. In addition, the variance in
baseline values indicates that inter-patient comparisons
may obscure differences even further, but individual patient
change may correct for this. Values such as the minimal
clinically important difference and the acceptable symptom
state are of assistance in this regard [10, 12]. We prefer
measuring traditional outcomes as well (such as morphine
consumption and pain scores) in addition to the QoR-15 to
reduce the risk of a false-negative intervention. Second,
after several studies comparing interventions with i.v.
opioids in robot-assisted radical prostatectomy procedures,
a new study may aim to compare two interventions, for
example, intrathecal analgesia vs. transversus abdominus
plane block. We believe that an intervention should have
been compared with the least invasive strategy ﬁrst before
an additional value could be concluded. For intrathecal
morphine in a robot-assisted radical prostatectomy
procedure, this was insufﬁciently done when this study was
initiated.
In conclusion, this study showed that a single shot
of intrathecal bupivacaine/morphine reduced the
decrease in quality of recovery in the ﬁrst 24 h after
robot-assisted radical prostatectomy in a limited manner.
There were important reductions in opioid consumption,
sedation, bladder spasms, number of patients with
severe pain and need for rescue medication. Despite a
modest increase in the incidence of pruritus, multimodal
pain management with intrathecal bupivacaine/morphine
remains a viable option for robot-assisted radical
prostatectomy.
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